ANTHONY KALES, M.D.; CONSTANTIN R. SOLDATOS, M.D.; ROGER CADIEUX, M.D.; EDWARD O. BIXLER, Ph.D.; TJIAUWLING TAN, M.D.; MARTIN B. SCHARF, Ph.D.
Narcolepsy is being treated with stimulant drugs (amphetamines or methylphenidate) to control the excessive daytime sleepiness and sleep attacks, and imipramine to manage auxiliary symptoms, particularly cataplexy (1). The potentials for tolerance and dependence with the stimulants and cardiotoxicity from imipramine underscore the need for other therapies.
In 1978, we administered propranolol to a narcoleptic patient to treat premature ventricular contractions; a detailed report has been published elsewhere (2). When a relatively low dose of propranolol reduced the frequency of narcoleptic and cataplectic attacks, we gradually increased the dose. At a daily dose of about 300 mg, the attacks were
KALES A, SOLDATOS CR, CADIEUX R, BIXLER EO, TAN T, SCHARF MB. Propranolol in the Treatment of Narcolepsy. Ann Intern Med. ;91:741–743. doi: 10.7326/0003-4819-91-5-741
Download citation file:
Published: Ann Intern Med. 1979;91(5):741-743.
Cardiology, Coronary Risk Factors, HIV, Hypertension, Infectious Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use